Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment

• Sponsor: Ankara Training and Research Hospital (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05109377
• Collaborator: (none)
• Enrollment: 90
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 5.7
• Patients Per Site Per Month: 15.7

Study Details

Study Description

Brief Summary

The investigators analyze the patients' endocan levels, IIEF scores, and hormon levels both before and after tadalafil (5 or 20mg) treatment. The investigators want to see erectile dysfunction severity and tadalafil treatment relations with endocen level.

Condition or Disease	Intervention/Treatment	Phase
Erectile Dysfunction	Diagnostic Test: Endocan; Drug: tadalafil	N/A

Detailed Description

The investigators will include at least 90 patients in study. Blood tests will taken before and after tadalafil treatment and will store at -80 celcius degree.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Diagnostic
• Official Title: Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment
• Actual Study Start Date: Jun 24, 2021
• Anticipated Primary Completion Date: Nov 15, 2021
• Anticipated Study Completion Date: Dec 15, 2021

Arms and Interventions

Arm	Intervention/Treatment
Other: 5mg tadalafil 5mg tadalafil	Diagnostic Test: Endocan; Endocan will measured before and after treatment; Drug: tadalafil; tadalafil
Other: 20mg tadalafil 20 mg tadalafil	Diagnostic Test: Endocan; Endocan will measured before and after treatment; Drug: tadalafil; tadalafil

Outcome Measures

Primary Outcome Measures

1. Rates of IIEF Score [1 month]

   Levels of Endocan relationship with IIEF

Secondary Outcome Measures

1. Levels of Endocan [1 month]

   Levels of Endocan with tadalafil treatment

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Patients with erectile dysfuction

Exclusion Criteria:

• Psychogenic erectile dysfunction

• Erectile dysfunction associated with hormonal disorders

• Drug related erectile dysfunction

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Veysel Bayburtluoğlu	Ankara		Turkey

Sponsors and Collaborators

• Ankara Training and Research Hospital

Investigators

• Principal Investigator: Veysel Bayburtluoğlu, Ministry of Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Veysel Bayburtluoğlu, Principal Investigator, Ankara Training and Research Hospital
• ClinicalTrials.gov Identifier: NCT05109377
• Other Study ID Numbers: E-93471371-514.10
• First Posted: Nov 5, 2021
• Last Update Posted: Nov 5, 2021
• Last Verified: Nov 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Veysel Bayburtluoğlu, Principal Investigator, Ankara Training and Research Hospital: Endocan; Erectile dysfunction; Tadalafil
• Additional relevant MeSH terms: Erectile Dysfunction; Tadalafil

Study Results

No Results Posted as of Nov 5, 2021